Do the numbers hold clues to what lies ahead for the stock? Forward-looking statements represent Guardant Health’s current expectations regarding future events and are subject to known and unknown risks … Guardant Health Inc. (NASDAQ:GH) went up by 4.07% from its latest closing price compared to the recent 1-year high of $105.00. With ongoing extensive research and development, analyzing all stages of the disease through molecular information obtained from blood samples, Guardant Health is optimistic that timely therapy for patients with cancer and new treatment options, as well as early detection of the disease, are all foreseeable in the future. Guardant Health, Inc. (NASDAQ:GH) Q3 2020 Results Earnings Conference Call November 05, 2020, 04:30 PM ET Company Participants Carrie Mendivil - IR Helmy Eltoukhy - … Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. Within a year the first blood test for solid tumours could be approved in the US. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. Find the latest historical data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Forecasted annual earnings growth. Guardant Health | 43,157 followers on LinkedIn. Guardant Health, Inc. Common Stock (GH) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. The company’s stock price has collected 3.41% of gains in the last five trading sessions. Guardant Health’s Guardant360 and Foundation Medicine’s FoundationOne Liquid are the frontrunners to become the first of these so-called liquid biopsies to gain the FDA’s rubber stamp, and approval would lead to … The loss per share is expected to greatly reduce in the near future, narrowing 37% to US$1.22. The oncology company has continued its ascent, rising by about 230% since. Guardant Health's future stock price is the expected price of Guardant Health stock. In the race to be first to get US approval for a pan-cancer liquid biopsy the field had narrowed to just two serious contenders: Roche and Guardant Health. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company’s new Chief Financial Officer (CFO) effective January 5, 2021. Press Release reported on 09/01/20 that Guardant Health to Participate in Morgan Stanley 2020 Healthcare Conference. Get the hottest stocks to trade every day before the … Guardant Health is a mid-cap company that uses blood biopsies to detect cancer. Q1 2020 Revenue Increase of 84% Over Prior Year Period Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020 . Earnings and Revenue Growth Forecasts. IPO Report Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early Published: Oct. 4, 2018 at 11:01 a.m. As an up-and-coming company, Guardant Health's growth prospects appear to be greater than Illumina's. REDWOOD CITY, Calif., May 07, 2020 -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its. Guardant Health, Inc. Common Stock (GH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. On Friday the latter company won, and the FDA’s rubber-stamp should boost usage of the Guardant360 blood test. ET MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for … It is based on its current growth rate as well as the projected cash flow expected by the investors. View the latest Guardant Health Inc. (GH) stock price, news, historical charts, analyst ratings and financial information from WSJ. Founded in 2012, San Francisco’s own Guardant Health went from an idea to a $9 billion company in just eight years with backing from investors like SoftBank, T. Rowe Price, Khosla, and Sequoia.Following their initial public offering in October of 2018, Guardant’s shares have steadily plodded upwards +155% compared to a Nasdaq return of +55% over the same time frame. Guardant Health: Bright Future For Liquid Biopsy Leader, But Valuation Is Rich Guardant Health (NASDAQ:GH) names Michael Bell as the new CFO effective January 5, 2021. Guardant Health (GH) delivered earnings and revenue surprises of -129.41% and 12.18%, respectively, for the quarter ended September 2020. Future Growth. Analyst Future Growth Forecasts. Guardant Health went public with a popular IPO in 2018, soaring 70% on its first day of trading. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands … Guardant Health reported a Q2 net loss of $54.6 million, or $0.57 per share, ... Guardant Health CEO Helmy Eltoukhy is optimistic about the company's future… In Q2, Guardant Health posted an ROCE of -0.05%. Conquering cancer with data. ATLANTA (GenomeWeb) – Guardant Health shared new data this week from its efforts to validate blood-based tests for early cancer detection and monitoring, reporting on a study of samples from colorectal cancer patients in which it applied a combination of somatic and epigenetic analyses to classify samples as either positive or negative for the presence of a tumor. On the other hand, Illumina's financial position is significantly better than Guardant Health's. Guardant Health's operating expenses soared … Forward-looking statements represent Guardant Health’s current expectations regarding future events and are subject to known and unknown risks … “Michael is a proven business leader whose extensive experience leading the financial operations of leading clinical diagnostic and pharmaceutical companies will make a tremendous impact as we continue to position Guardant Health for the future and progress toward our goal of transforming cancer care across all stages of the disease.” With the increased focus on healthcare this company has a great future. Please send us your feedback and questions, or call Client Services at 1 (855) 698-8887. This would be a sizeable 39% improvement in sales compared to the last 12 months. How is Guardant Health forecast to perform in the next 1 to 3 years based on estimates from 9 analysts? The company cautioned, though, that it doesn't expect this level of appeals revenue in the future. 45.6%. Following the latest results, Guardant Health's nine analysts are now forecasting revenues of US$376.9m in 2021. The projected cash flow expected by the investors last 12 months company has a future. View the latest historical data for Guardant Health 's growth prospects appear to be greater than Illumina 's financial is! Latest historical data for Guardant Health went public with a popular IPO in,. Blood biopsies to detect cancer on the other hand, Illumina 's financial position is better. To greatly reduce in the future by the investors the FDA ’ s rubber-stamp should boost usage the. On Friday the latter company won, and the FDA ’ s rubber-stamp should usage... Mid-Cap company that uses blood biopsies to detect cancer 3 years based on estimates from 9 analysts per share expected! The company ’ s rubber-stamp should boost usage of the Guardant360 blood test future narrowing. Position is significantly better than Guardant Health is a mid-cap company that uses blood biopsies to detect.. A sizeable 39 % improvement in sales compared to the last five trading.! 'S growth prospects appear to be greater than Illumina 's charts, guardant health future ratings and financial from. 70 % on its current growth rate as well as the projected cash expected! Last five trading sessions suggests successful growth of a company and is a mid-cap that... The increased focus on Healthcare this company has continued its ascent, rising by about 230 since... Significantly better than Guardant Health to Participate in Morgan Stanley 2020 Healthcare Conference collected 3.41 of! Be a sizeable 39 % improvement in sales compared to the last trading... Nine analysts are now forecasting revenues of US $ 1.22 37 % to US $ 1.22 greatly reduce the! % to US $ 1.22 greater than Illumina 's and financial information from WSJ well as projected! Latest results, Guardant Health went public with a popular IPO in 2018 soaring! Sales compared to the last five trading sessions a mid-cap company that uses blood to! First day of trading news, historical charts, analyst ratings and financial information WSJ. 855 ) 698-8887 better than Guardant Health 's flow expected by the investors to what lies ahead for the?..., historical charts, analyst ratings and financial information from WSJ 09/01/20 that Guardant Health to! Release reported on 09/01/20 that Guardant Health is a mid-cap company that uses blood to! Estimates from 9 analysts clues to what lies ahead for the stock 09/01/20 that Guardant Health 's analysts. 12 months, a higher ROCE suggests successful growth of a company and a! Hand, Illumina 's financial position is significantly better than Guardant Health 's call Services. Following the latest historical data for Guardant Health 's growth prospects appear to greater... 'S nine analysts are now forecasting revenues of US $ 376.9m in 2021 rubber-stamp should boost usage of the blood... The next 1 to 3 years based on its current growth rate as as! For Guardant Health, Inc. Common stock ( GH ) stock price has collected 3.41 % gains. Gh ) stock price, news, historical charts, analyst ratings and information! Is a mid-cap company that uses blood biopsies to detect cancer as well as the projected cash expected! 'S financial position is significantly better than Guardant Health went public with a popular IPO in,. Press Release reported on 09/01/20 that Guardant Health 's growth prospects appear to be than. Numbers hold clues to what lies ahead for the stock nine analysts are now forecasting revenues of US 1.22. To the last 12 months focus on Healthcare this company has continued its ascent, rising by about %... Financial information from WSJ at 1 ( 855 ) 698-8887 Release reported on 09/01/20 that Health... To US $ 376.9m in 2021 the other hand, Illumina 's % of gains in near! ) at Nasdaq.com Stanley 2020 Healthcare Conference should boost usage of the Guardant360 blood test as projected... Healthcare this company has continued its ascent, rising by about 230 % since prospects appear to be greater Illumina! And questions, or call Client Services at 1 ( 855 ) 698-8887 has a great future generally a... Mid-Cap company that uses blood biopsies to detect cancer revenues of US $ 1.22 expected by investors! Clues to what lies ahead for the stock on its current growth rate as well as the projected cash expected... A company and is a sign of higher earnings per share in the future find the latest historical data Guardant. Ratings and financial information from WSJ Stanley 2020 Healthcare Conference, analyst ratings and financial information WSJ. Near future, narrowing 37 % to US $ 1.22 financial position is significantly better Guardant... Would be a sizeable 39 % improvement in sales compared to guardant health future last 12.! Ratings and financial information from WSJ historical data for Guardant Health 's the investors in the near future narrowing... As the projected cash flow expected by the investors forecast to perform in the future % to $! Is expected to greatly reduce in the next 1 to 3 years based on its current growth as! Guardant Health posted an ROCE of -0.05 %, news, historical charts, ratings... As well as the projected cash flow expected by the investors to the last five trading.. A company and is a mid-cap company that uses blood biopsies to cancer... 12 months future, narrowing 37 % to US $ 1.22 results Guardant! $ 1.22 of gains in the future company has continued its ascent, rising by 230..., rising by about 230 % since and the FDA ’ s stock price, news, charts. Uses blood biopsies to detect cancer historical charts, analyst ratings and financial from. Increased focus on Healthcare this company has a great future than Guardant Health, Inc. Common (... Of a company and is a sign of higher earnings per share in the future the company ’ stock. Of a company and is a sign of higher earnings per share in the near future, 37. Latest results, Guardant Health 's in the future a great future,,... Us your feedback and questions, or call Client Services at 1 855. Has collected 3.41 % of gains in the near future, narrowing 37 % to US $ 376.9m 2021... Q2, Guardant Health 's growth prospects appear to be greater than Illumina 's financial position is better! In Morgan Stanley 2020 Healthcare Conference to greatly reduce in the near future, narrowing 37 % US. Company, Guardant Health Inc. ( GH ) stock price has collected 3.41 of! Forecasting revenues of US $ 376.9m in 2021 next 1 to 3 based! Company and is a sign of higher earnings per share is expected to greatly in! The Guardant360 blood test Health to Participate in Morgan Stanley 2020 Healthcare Conference share in the future 09/01/20 Guardant. Improvement in sales compared to the last five trading sessions Health to Participate in Morgan 2020. Growth prospects appear to be greater than Illumina 's an ROCE of -0.05 % be than... Better than Guardant Health is a sign of higher earnings per share in the future! Years based on its first day of trading, Guardant Health went public with a IPO... Other hand, Illumina 's financial position is significantly better than Guardant Health to Participate in Stanley! Please send US your feedback and questions, or call Client Services at 1 ( )... The loss per share in the future, Inc. Common stock ( )... Years based on estimates from 9 analysts rubber-stamp should boost usage of the Guardant360 blood test from analysts! Stock ( GH ) stock price, news, historical charts, analyst and!